Can You Take Tirzepatide While Pregnant?

No, you should not take tirzepatide while pregnant. Tirzepatide, the active ingredient in Mounjaro and Zepbound, is not recommended during pregnancy because there are no adequate human safety studies, and animal studies have shown fetal growth abnormalities and skeletal malformations at clinically relevant doses. The U.S. Food and Drug Administration (FDA) advises patients to stop tirzepatide when pregnancy is recognized and to discontinue the medication at least one to two months before trying to conceive. Weight loss itself is not recommended during pregnancy because a developing baby needs adequate calories and nutrients to grow properly.

This article explains why tirzepatide is not safe during pregnancy, what the animal studies actually found, how long you should be off the medication before conceiving, how tirzepatide affects birth control, what to do if you become pregnant while taking it, and how to manage your weight safely during pregnancy without GLP-1 weight loss medication.

Why Is Tirzepatide Not Safe During Pregnancy?

Tirzepatide is not safe during pregnancy because no adequate human studies have been conducted to determine its effects on a developing fetus, and animal reproduction studies have demonstrated harmful outcomes including fetal malformations and reduced fetal weight. Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It works by mimicking two hormones that regulate blood sugar, slow stomach emptying, and reduce appetite. Those same mechanisms create concerns during pregnancy.

The primary safety concern is nutritional. Tirzepatide commonly causes nausea, vomiting, diarrhea, and decreased appetite. During pregnancy, adequate caloric intake and balanced nutrition are critical for fetal organ development, especially during the first trimester when the brain, heart, kidneys, and spine are forming. A medication that suppresses appetite and slows digestion can make it harder for a pregnant person to consume enough nutrients to support healthy fetal growth. According to the American Diabetes Association (ADA), poorly controlled nutrition and blood sugar during pregnancy increase the risk of major birth defects, stillbirth, and macrosomia (abnormally large birth weight).

The second concern is the direct biological effect. In animal reproduction studies submitted to the FDA, pregnant rats given tirzepatide during organogenesis (the critical window when organs form) at 0.5-fold the maximum recommended human dose (MRHD) showed increased incidences of external, visceral, and skeletal malformations. Pregnant rabbits given tirzepatide during the same developmental window showed fetal growth reductions at clinically relevant exposures. The FDA prescribing information for both Mounjaro and Zepbound states plainly that available human data are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Until human studies establish safety, the clinical recommendation is to avoid tirzepatide entirely during pregnancy.

Can Tirzepatide Cause Birth Defects?

The FDA has not established a definitive link between tirzepatide and birth defects in humans because there are no adequate controlled studies in pregnant people, but animal studies have shown fetal abnormalities at doses relevant to human treatment. The distinction matters: the absence of confirmed human harm does not mean the medication is safe. It means the risk is unknown, and the animal data provides enough reason for caution.

The animal findings raise an important question: were the fetal abnormalities caused by tirzepatide itself, or by the maternal weight loss and reduced food intake the drug produced? The FDA prescribing information acknowledges that the adverse embryo-fetal effects in animals coincided with pharmacological effects on maternal weight and food consumption, meaning the two factors are difficult to separate. Regardless of the mechanism, the outcome is the same for clinical decision-making: weight loss injections that reduce maternal nutrition during pregnancy carry risk to fetal development, whether that risk comes from the drug directly or from the caloric restriction it produces.

The background risk of major birth defects in the general U.S. population is approximately 2% to 4%, according to the Centers for Disease Control and Prevention (CDC). The risk of miscarriage in clinically recognized pregnancies ranges from 15% to 20%. For women with poorly controlled diabetes, those baseline risks are higher because elevated blood sugar during early pregnancy is independently associated with increased rates of congenital malformations affecting the heart, brain, kidneys, and spine. This makes the conversation about tirzepatide and pregnancy especially important for patients who take the medication for type 2 diabetes management, because stopping tirzepatide without a safe alternative can also harm the pregnancy through uncontrolled blood sugar.

How Long Should You Be Off Tirzepatide Before Pregnancy?

You should be off tirzepatide for at least 25 to 30 days before trying to conceive, and the FDA recommends a buffer of one to two months to confirm the medication has fully cleared your system. Tirzepatide has an elimination half-life of approximately 5 days, which means it takes about five half-lives, roughly 25 days, for the drug to be substantially eliminated from the body. Some providers recommend extending the washout period to a full two months as an additional safety buffer.

The timing matters because of organogenesis. The critical period when the fetus’s major organs form occurs during weeks 3 through 8 of gestation, counted from the first day of the last menstrual period. Many women do not recognize pregnancy until week 4 to 6. If tirzepatide is still circulating in the body during those early weeks, the fetus is potentially exposed during the most vulnerable phase of development. By stopping tirzepatide at least one month before trying to conceive, you give the drug time to clear your system before the embryo begins forming its major organ systems.

We advise our patients here in Lee’s Summit who are considering pregnancy to schedule a consultation specifically to discuss their medical weight loss plan and transition timeline. The goal is to create a clear, safe plan that protects both the patient and the future pregnancy.

Does Tirzepatide Affect Birth Control?

Yes, tirzepatide affects birth control because it slows gastric emptying, which can reduce how effectively the body absorbs oral contraceptive pills. The FDA prescribing information for both Mounjaro and Zepbound specifically warns that tirzepatide may decrease the effectiveness of oral birth control. The recommendation is to switch to a non-oral contraceptive method or add a barrier method (like condoms) for four weeks after starting tirzepatide and for four weeks after each dose increase.

The mechanism is straightforward. Tirzepatide delays how quickly food and medications move from the stomach into the small intestine, where most oral drugs are absorbed. Oral birth control pills rely on consistent absorption to maintain steady hormone levels. Slower gastric emptying means the pill spends more time in the stomach and less time being absorbed in the intestine, which can reduce the hormone concentration in the bloodstream. The result is a higher chance of breakthrough ovulation and unintended pregnancy.

Better birth control options while taking tirzepatide include methods that bypass the digestive system entirely:

1. Intrauterine devices (IUDs), both hormonal and copper, which are placed directly in the uterus and are unaffected by gastric emptying
2. Contraceptive implants (like Nexplanon), which release hormones directly into the bloodstream through a small rod placed under the skin of the upper arm
3. Contraceptive injections (like Depo-Provera), which deliver hormones via intramuscular injection every three months
4. Barrier methods (condoms, diaphragms), which physically prevent sperm from reaching the egg and are not affected by any medication
5. Vaginal rings (like NuvaRing), which deliver hormones through the vaginal mucosa rather than the GI tract

If you are currently taking oral birth control and starting tirzepatide, talk to your prescribing provider about switching to one of these non-oral methods before your first injection. The four-week overlap recommendation applies after every dose increase, not just the initial dose, because higher doses produce stronger gastric emptying delays.

What Is the “Ozempic Baby Boom”?

The “Ozempic baby boom” refers to a widely reported trend of unplanned pregnancies among women taking GLP-1 receptor agonist medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), including women who had previously struggled with infertility. The term originated on social media platforms like TikTok and Reddit, where women began sharing their surprise pregnancy stories after starting GLP-1 medications for weight loss or diabetes management. The Facebook group “I got pregnant on Ozempic” now has more than 500 members.

The phenomenon has a biological explanation rooted in the connection between body weight, insulin resistance, and ovulation. Approximately 7% to 10% of U.S. women of reproductive age have polycystic ovary syndrome (PCOS), according to UT Southwestern Medical Center. PCOS is characterized by insulin resistance, excess estrogen production, irregular or absent menstrual cycles, and difficulty ovulating. Excess body weight worsens all of these symptoms. When women with PCOS or obesity-related infertility lose even 10% of their body weight, their symptoms often improve significantly: menstrual cycles become more regular, ovulation resumes, and the chance of natural conception increases.

GLP-1 medications produce exactly that level of weight loss in many patients. In the SELECT trial, 44% of patients using semaglutide lost more than 10% of their body weight within two years, according to research co-authored by UT Southwestern endocrinologist Dr. Ildiko Lingvay. A 2025 review of 12 small trials suggested modest gains in natural conception rates among women taking GLP-1 medications. Combined with the potential reduction in oral contraceptive effectiveness from slowed gastric emptying, these metabolic and hormonal improvements explain why unplanned pregnancies are occurring in women who had not previously been able to conceive.

The important takeaway is that improved fertility is an indirect effect of the weight loss and metabolic changes these medications produce, not a direct pharmacological effect. GLP-1 medications are not fertility treatments. But patients taking them should be aware that their ability to become pregnant may increase, and they should use reliable non-oral contraception throughout treatment if pregnancy is not desired.

What Should You Do If You Get Pregnant While Taking Tirzepatide?

If you get pregnant while taking tirzepatide, you should stop the medication immediately and contact your healthcare provider right away. An unplanned pregnancy on tirzepatide does not automatically mean the baby will be harmed. The animal data raises concern, but it does not predict outcomes in every human pregnancy. What matters most is acting quickly to eliminate the exposure and transition to a pregnancy-safe care plan.

Take these steps immediately:

• Stop taking tirzepatide as soon as you confirm the pregnancy. Do not take your next scheduled dose.
• Contact your prescribing provider within 24 hours. They will help you transition to a pregnancy-safe treatment plan for blood sugar management if you have diabetes.
• Schedule an early prenatal ultrasound with your OB-GYN to assess fetal development and establish a monitoring timeline.
• Report the pregnancy to Eli Lilly’s pregnancy exposure registry by calling 1-800-LillyRx (1-800-545-5979). This voluntary registry collects safety data that helps researchers understand how tirzepatide exposure during pregnancy affects outcomes.
• Discuss prenatal nutrition with your provider to confirm you are consuming adequate calories, folic acid, and essential nutrients to support fetal growth now that the appetite-suppressing effect of tirzepatide will gradually wear off over the next 25 to 30 days.

For patients who were taking tirzepatide for type 2 diabetes, the transition typically involves switching to insulin, which is the gold standard for blood sugar management during pregnancy. Insulin does not cross the placenta in clinically significant amounts and has decades of established safety data. The ADA recommends target blood glucose levels during pregnancy of fasting glucose below 95 mg/dL and one-hour postprandial glucose below 140 mg/dL. Your endocrinologist or maternal-fetal medicine specialist will determine the right insulin regimen based on your individual glucose patterns.

Can You Take Tirzepatide While Breastfeeding?

There is no clinical data confirming whether tirzepatide is safe to take while breastfeeding. The National Library of Medicine’s LactMed database states that no information is available on the clinical use of tirzepatide during breastfeeding. However, the database notes that due to tirzepatide’s high molecular weight of 4,814 Daltons, absorption through breast milk is likely to be low. The infant’s gastrointestinal tract would also likely partially destroy the protein before it could be absorbed systemically.

Despite the low theoretical risk, most providers recommend caution. The decision to use tirzepatide while breastfeeding should involve a discussion between the patient and their provider, weighing the benefits of continued weight management against the unknown risk to the nursing infant. Women who want to resume tirzepatide after pregnancy should discuss the timing with their provider, factoring in how long they plan to breastfeed and whether alternative weight management strategies can bridge the gap.

How to Manage Weight During Pregnancy Without Tirzepatide

Managing weight during pregnancy without tirzepatide involves structured nutrition, safe physical activity, and close monitoring with your healthcare team. Weight loss is generally not recommended during pregnancy, but maintaining a healthy weight gain trajectory and managing blood sugar are both achievable through lifestyle approaches alone for many patients.

The American College of Obstetricians and Gynecologists (ACOG) and the ADA recommend a minimum of 175 grams of carbohydrates per day for women with gestational diabetes, with a focus on high-fiber, complex carbohydrate sources like fruits, vegetables, legumes, and whole grains rather than refined sugars. Protein intake from plant sources, fish, and lean meats supports insulin sensitivity. Moderate-intensity physical activity of at least 150 minutes per week, spread across multiple days, is also recommended. Walking, stationary cycling, and swimming are safe options for most pregnant patients.

For patients who were taking tirzepatide for weight loss rather than diabetes, the transition may be simpler. Without a diabetes diagnosis, the primary concern is maintaining healthy eating habits established during treatment without the appetite-suppressing support of the medication. We work with our medical weight loss patients to build sustainable nutrition habits that continue to serve them during pregnancy and beyond, so that the progress they made on tirzepatide does not reverse once the medication stops.

Patients with type 2 diabetes who stop tirzepatide for pregnancy typically transition to insulin under the guidance of their endocrinologist. Hormone therapy during and after pregnancy is a separate but related conversation for patients experiencing hormonal shifts that affect weight, mood, and metabolism. Your care team should address all of these factors together rather than in isolation.

Frequently Asked Questions

Are Weight Loss Injections Safe While Pregnant?

No, weight loss injections are not safe while pregnant. This applies to all GLP-1 receptor agonists, including tirzepatide (Mounjaro, Zepbound), semaglutide (Ozempic, Wegovy), and liraglutide (Saxenda). None of these medications have been studied in adequate controlled trials in pregnant humans, and all carry animal data showing potential fetal harm. Weight loss itself is not recommended during pregnancy. The FDA advises discontinuing all GLP-1 medications when pregnancy is recognized.

Is Semaglutide Safer Than Tirzepatide During Pregnancy?

No, semaglutide is not considered safer than tirzepatide during pregnancy. Both medications lack adequate human pregnancy data, and both carry animal study findings showing potential fetal harm. The FDA prescribing information for Ozempic and Wegovy contains similar pregnancy warnings to those found on the Mounjaro and Zepbound labels. Neither medication is recommended during pregnancy, and the clinical recommendation to stop at least one to two months before conception applies to both. Patients should not switch from one GLP-1 to another in an attempt to find a “pregnancy-safe” option, because no GLP-1 medication meets that standard.

What Happens If You Get Pregnant on a GLP-1?

If you get pregnant on a GLP-1 medication, stop the medication immediately and contact your healthcare provider. Early exposure does not guarantee adverse outcomes, but it does require prompt medical evaluation. Your provider will schedule early prenatal monitoring, may refer you to a maternal-fetal medicine specialist, and will transition you to pregnancy-safe alternatives for blood sugar management if needed. Reporting the pregnancy to the manufacturer’s registry also helps researchers build the human safety data that is currently lacking.

Can GLP-1 Medications Improve Fertility?

GLP-1 medications can indirectly improve fertility by promoting weight loss, reducing insulin resistance, and restoring regular ovulation in women with PCOS or obesity-related infertility. A 2024 scoping review in Cureus found that GLP-1 receptor agonists were associated with reductions in body weight and BMI, improvements in glucose regulation, better menstrual regularity, and higher rates of natural pregnancy in women with PCOS. These fertility improvements are a byproduct of the metabolic changes the medications produce, not a direct pharmacological effect. GLP-1 medications are not FDA-approved as fertility treatments.

What Vitamins Should You Take While on Tirzepatide?

Patients taking tirzepatide should discuss vitamin supplementation with their provider, especially since the medication reduces appetite and food intake. Common recommendations include a daily multivitamin, vitamin B12 (because GLP-1 medications may reduce B12 absorption over time), vitamin D, and folic acid for women of childbearing age. Adequate folic acid intake, at least 400 micrograms daily, is especially important for women who could become pregnant, because folic acid reduces the risk of neural tube defects during the earliest weeks of fetal development. Vitamin shots can help patients who struggle to maintain adequate nutrient levels through diet alone while on appetite-suppressing medication.

The Bottom Line

Tirzepatide should not be taken during pregnancy. No human safety data exists, and animal studies show fetal malformations and growth reductions at clinically relevant doses. The FDA recommends stopping tirzepatide at least one to two months before trying to conceive and switching to non-oral contraception while on the medication to prevent unplanned pregnancy. If you become pregnant while taking tirzepatide, stop the medication immediately and contact your provider. The “Ozempic baby boom” is real, driven by GLP-1 medications restoring fertility in women with PCOS and obesity, and every patient taking these medications should have a clear contraception and pregnancy plan in place.

If you are currently on a GLP-1 weight loss program and thinking about pregnancy, or if you need help building a transition plan, we are here to help. At Slimming Solutions Med Spa in Lee’s Summit, we work with patients at every stage of their weight loss journey, including the transition off medication when pregnancy planning begins. Call us at (816) 524-3438 to schedule a consultation.